During the past decade, Providence Heart and Vascular Institute conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 13 clinical trials were completed, i.e. on average, 65% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 7 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence Heart and Vascular Institute" #1 sponsor was "Abbott Medical Devices" with 13 trials, followed by "Edwards Lifesciences" with 7 trials sponsored, "Boston Scientific Corporation" with 2 trials sponsored, "HealthCore-NERI" with 2 trials sponsored and "Arginox Pharmaceuticals" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence Heart and Vascular Institute" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "Massachusetts General Hospital" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Acelis Connected Health" with 1 trials as a collaborator and "Albany Stratton VA Medical Center" with 1 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 42 trials.

According to Clinical.Site data, the most researched conditions in "Providence Heart and Vascular Institute" are "Heart Failure" (9 trials), "Aortic Stenosis" (4 trials), "Coronary Artery Disease" (4 trials), "Cardiovascular Diseases" (3 trials) and "Peripheral Arterial Disease" (3 trials). Many other conditions were trialed in "Providence Heart and Vascular Institute" in a lesser frequency.

Most popular intervention types in "Providence Heart and Vascular Institute" are "Device" (30 trials), "Drug" (6 trials), "Procedure" (3 trials), "Behavioral" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "ABT NG DES 48 EECSS" (1 trials), "ACURATE Prime™ Transfemoral TAVR System XL" (1 trials), "ACURATE neo2™ Transfemoral TAVR System" (1 trials) and "AMPLATZER™ PFO Occluder" (1 trials). Other intervention names were less common.

The vast majority of trials in "Providence Heart and Vascular Institute" are 36 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Providence Heart and Vascular Institute". undefined are not yet recruiting, 8 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Providence Heart and Vascular Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Providence Heart and Vascular Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 25 trials that are defined as “Not Applicable".